What data supports the use of novel nonsteroidal MRAs in patients already on an SGLT2 inhibitor?
Normand Proulx, MD, FRCP(C)
Voyez ce que notre groupe d’experts multidisciplinaire et pancanadien a à dire sur l’insuffisance rénale chronique issue du diabète de type 2, dans le cadre de la série Caucus de couloir. Chaque vidéo de 5 à 10 minutes met en vedette un de nos experts qui font le point sur le dépistage, les lignes directrices, le risque résiduel et les nouveaux traitements relatifs à l’IRC issue de diabète de type 2. Rendez-vous sur Ukidney.com pour regarder les vidéos dès maintenant!
.
Au terme de ce programme, les participants seront en mesure de :
Quand et pourquoi un rapport albumine/créatinine devrait-il être calculé chez les patients atteints de diabète de type 2?
Navdeep Tangri, MD PhD, FRCPC
Que disent les lignes directrices sur la prise en charge de l’IRC chez les patients atteints de diabète de type 2?
Alice Y.Y. Cheng, MD, FRCPC
Quelles sont les principales différences entre les ARM stéroïdiens et les ARM non stéroïdiens?
Daniel Ngui, BScPT, PT, MD, CCFP, FCFP
Pour quels patients doit-on envisager l’utilisation des nouveaux ARM non stéroïdiens?
Normand Proulx, MD, FRCP(C)
Quelles données soutiennent l’emploi des nouveaux ARM non stéroïdiens chez les patients déjà traités avec un inhibiteur de SGLT2?
Normand Proulx, MD, FRCP(C)
Quand et comment surveiller et gérer le taux de potassium chez les patients traités avec un ARM?
Louise Moist, MD MSc CCPE FRCPC
MD, FRCPC
MD, FRCP(C)
MD, MSc, CCPE, FRCPC
MD, PhD, FRCPC
BSc, PT, MD, CCFP, FCFP
These patient case studies are part of a wider programme entitled ‘Hyperkalaemia in Cardiorenal Disease’. Watch these short videos, where Dr Burton presents a CKD patient at high risk of hyperkalaemia, and Dr Zieroth presents a HF patient with moderate to severe hyperkalaemia. After the videos have played, you can vote using the polls on how you would treat these patients. These cases, and their management strategy, will be discussed during a live roundtable. The panel will discuss emerging data and the changing landscape of medical management of hyperkalaemia. If you’d like to register for this roundtable, please enter your email after completing the polls.
This programme is supported by an unrestricted educational grant from AstraZeneca and brought to you by Radcliffe Medical Education.
Dr. James Burton
Professor of Renal Medicine
University of Leicester, UK
Prof James Burton is Honorary Consultant Nephrologist and Professor of Renal Medicine and Associate Dean for Clinical Research at the University of Leicester, Leicester, UK. His principal research interests are the mechanisms underlying uraemic cardiovascular disease modification of cardiovascular risk in patients with end-stage renal disease and the identification and application of novel biomarkers.
In addition, Prof Burton is involved in the development and running of clinical trials; he is Chief Investigator for the NIHR funded NightLife trial investigating the impact of nocturnal dialysis on patient outcomes as well as the Kidney Research UK funded CONFIRM study exploring the utility of a novel cardiac magnetic resonance imaging (MRI) techniques in haemodialysis patients. Prof Burton is the independent Chair of two multi-centre NIHR Trial Steering Committees and sits on a number of others.
He is the current Chair of the UK Kidney Association Clinical Guidelines Committee and has himself chaired a number of UK guideline updates making sure that research translates into clinical practice.
Dr Shelley Zieroth
Professor at the College of Medicine
University of Manitoba, Canada
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St. Boniface Hospital in Winnipeg, CA.
She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba. She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Immediate Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She serves as Co-Chair of Canada’s largest annual heart failure meeting, HF Update and serves as Scientific Planning Committee Chair for the Canadian Cardiovascular Congress hosted by the Canadian Cardiovascular Society. She is currently President-elect of the Federation of Medical Women of Canada.
Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.
Led by world-renowned expert Dr. David Chereney, this presentation delves into emerging strategies beyond Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors in Chronic Kidney Disease (CKD) management. We explore novel pharmacotherapies, lifestyle modifications, and personalized approaches, navigating the evolving landscape of CKD care. Join us in charting the course for enhanced patient outcomes beyond the SGLT2 inhibitor era.
Following his clinical training in Nephrology, Dr. Cherney completed his PhD in human renal physiology at the Institute of Medical Science, University of Toronto in 2008. He is currently Professor of Medicine, University of Toronto and a Clinician Scientist at the University Health Network and Mount Sinai Hospitals, where he is a Senior Scientist and director of the Renal Physiology Laboratory.
He is currently supported by the Canadian Institutes of Health Research, the JDRF, the Heart and Stroke Richard Lewar Centre of Excellence, the Heart and Stroke Foundation of Canada and the Banting and Best Diabetes Centre. He is also supported by a Department of Medicine, University of Toronto Merit Award. Dr. Cherney’s research program focuses on physiological factors that initiate renal disease in patients with diabetes, such as renal hyperfiltration and inflammation, and the role of the cardiorenal axis in diabetes. His research group is also involved in early and late phase clinical trials in the cardiorenal-metabolic field, including several primary renal outcome trials in patients with and without diabetes. Dr. Cherney’s research program is closely aligned with his integrated and multidisciplinary cardiac-renal-endocrine clinic at the University Health Network, which maintains a strong emphasis on the prevention of diabetic nephropathy and cardiovascular disease. In 2019, he received the American Society of Nephrology (ASN) Distinguished Researcher Award for outstanding contributions to nephrology. In 2019 he also received the Diabetes Canada/CIHR – Institute of Nutrition Diabetes and Metabolism (INMD) Young Scientist Award.